Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Recruiting now · Phase 1

Conditions studied: T-Cell Acute Lymphoblastic Leukemia/Lymphoma

In brief

This will be a Phase 1, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with R/R T-ALL or T-LLy. BEAM-201 is an allogeneic anti-CD7 CART therapy.

Key facts

Study ID

NCT06934382

Run by

Stephan Grupp MD PhD

People needed

33

Starts

2025-04-29

Expected to finish

2031-05-30

Last updated by the study team

2026-07-07

Who can join

Age: any, up to 29. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.